TGTX - TG Therapeutics, Inc.
| Previous Close | 5.37 |
| Open | 5.32 |
| Bid | 5.15 x 1100 |
| Ask | 5.60 x 3100 |
| Day's Range | 5.23 - 5.59 |
| 52 Week Range | 4.20 - 17.35 |
| Volume | 854,612 |
| Avg. Volume | 1,665,018 |
| Market Cap | 441.365M |
| Beta (3Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.14 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.50 |
- Business Wire•18 hours ago
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of TG Therapeutics, Inc. Investors (TGTX)
Glancy Prongay & Murray LLP (“GPM”), a global investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that purchased or otherwise acquired TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) securities between June 4, 2018 and September 25, 2018, inclusive (the “Class Period”). TG Therapeutics investors have until December 3, 2018 to file a lead plaintiff motion. The complaint filed in this class action alleges that the Company made false and misleading statements to the market.
- ACCESSWIRE•19 hours ago
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 16, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TG Therapeutics, Inc. ("TG Therapeutics" or "the Company") (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between June 4, 2018 and September 25, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before December 3, 2018.
- GlobeNewswire•21 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Business Wire•yesterday
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In TG Therapeutics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (TGTX) of the December 3, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
- GlobeNewswire•yesterday
CLASS ACTION UPDATE for TGTX, ADNT and GOOG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, Nov. 16, 2018 -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies..
- GlobeNewswire•2 days ago
TGTX NOTICE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against TG Therapeutics, Inc.; Important Deadline – TGTX
NEW YORK, Nov. 15, 2018 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of TG.
- ACCESSWIRE•3 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
NEW YORK, NY / ACCESSWIRE / November 14, 2018 / Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (''TG'' or the ''Company'') (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. In a press release, TG announced that the trial's Data Safety Monitoring Board had met to review ongoing data from the UNITY-CLL study and advised the Company that the interim analysis of the ORR could not be conducted at that time because the data was not sufficiently mature to conduct the analysis.
- GlobeNewswire•3 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MCHP, TGTX, MGTI, HAS, CPB and ADNT
NEW YORK, Nov. 14, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- Business Wire•4 days ago
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of TG Therapeutics, Inc. Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors that purchased TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (NASDAQ: TGTX) securities between June 4, 2018 and September 25, 2018, inclusive (the “Class Period”). TG Therapeutics investors have until December 3, 2018 to file a lead plaintiff motion. Investors suffering losses on their TG Therapeutics investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
- GlobeNewswire•4 days ago
SHAREHOLDER ALERT: MCHP TGTX MGTI HAS CPB CHGG ADNT GOOG IGCC FIT RYAAY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 13, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•4 days ago
TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment
TG Therapeutics, Inc. (TGTX) today announced the first Company sponsored Phase I study of its novel, orally available and covalently-bound Bruton Tyrosine Kinase (BTK) inhibitor, TG-1701, is open for enrollment for patients with relapsed or refractory B-cell malignancies. The first cohort evaluating TG-1701 at a dose of 100 mg once-daily has been fully enrolled, and the first patient enrolled, a patient with relapsed/refractory Mantle Cell Lymphoma (MCL), achieved a partial response (PR) at the first efficacy assessment. The trial is first evaluating TG-1701 as a single agent, with subsequent cohorts designed to evaluate the triple combination of TG-1701 with ublituximab, the Company's novel glycoengineered anti-CD20 monoclonal antibody and umbralisib, the Company's novel PI3K delta inhibitor, the combination referred to as “U2”.
- GlobeNewswire•5 days ago
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against TG Therapeutics, Namaste, and Huazhu and Encourages Investors to Contact the Firm
NEW YORK, Nov. 12, 2018 -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of TG Therapeutics, Inc.,.
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG" or the "Company") (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. In a press release, TG announced that the trial's Data Safety Monitoring Board had met to review ongoing data from the UNITY-CLL study and advised the Company that the interim analysis of the ORR could not be conducted at that time because the data was not sufficiently mature to conduct the analysis.
- GlobeNewswire•5 days ago
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In TG Therapeutics, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in TG Therapeutics, Inc. (“TG Therapeutics” or the “Company”) (TGTX) of the December 3, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in TG Therapeutics stock or options between June 4, 2018 and September 25, 2018 and would like to discuss your legal rights, click here: www.faruqilaw.com/TGTX. There is no cost or obligation to you.
- GlobeNewswire•5 days ago
INVESTOR REMINDER NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TG Therapeutics, Inc. (“TG Therapeutics” or “the Company”) (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. TG Therapeutics was engaged in cleaning the data collected from its UNITY-CLL study, which gave it an understanding of the efficacy of the combination therapy.
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX) & Lead Plaintiff Deadline - December 3, 2018
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against TG Therapeutics, Inc. (''TG Therapeutics'' or the ...
- GlobeNewswire•6 days ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ADNT, GOOG, IGC and ALGN
NEW YORK, Nov. 11, 2018 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- GlobeNewswire•8 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Thomson Reuters StreetEvents•8 days ago
Edited Transcript of TGTX earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 TG Therapeutics Inc Earnings Call
- GlobeNewswire•8 days ago
SHAREHOLDER ALERT: TGTX CPB CHGG ADNT GOOG IGC ALGN SYF RYAAY AQUA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, Nov. 09, 2018 -- The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•8 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against TG Therapeutics, Inc. (TGTX)
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against TG Therapeutics, Inc. ("TG Therapeutics" ...
- Zacks•8 days ago
TG Therapeutics (TGTX) Reports Q3 Loss, Misses Revenue Estimates
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 21.82% and -5.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•8 days ago
TG Therapeutics: 3Q Earnings Snapshot
On a per-share basis, the New York-based company said it had a loss of 43 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was ...
- GlobeNewswire•8 days ago
TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2018 Financial Results
Investor Conference Call to be Held Today, Friday, November 9, 2018 at 8:30 AM ET NEW YORK, Nov. 09, 2018 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its.
- ACCESSWIRE•9 days ago
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against TG Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 8, 2018 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against TG Therapeutics, Inc. ("TG Therapeutics" or "the Company") (NASDAQ: TGTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares between June 4, 2018 and September 25, 2018, inclusive (the "Class Period"), are encouraged to contact the firm before December 3, 2018.
